BETH ISRAEL DEACONESS MEDICAL CENTER

A randomized clinical trial involving 50 physicians found that using a large language model (LLM) did not significantly improve diagnostic reasoning performance compared to conventional resources. The LLM alone outperformed both physician groups, indicating a need for further development in human-computer interactions to effectively integrate LLMs into clinical practice.

Cancer diagnosis linked to higher bankruptcy risk, lower credit scores, and persistent financial challenges, even in states with universal health care coverage.

Prescription digital therapeutics for mental health face concerns over patient privacy, gamification, and logistics. FDA-approved examples include DaylightRx for GAD, Rejoyn for MDD, MamaLift Plus for PPD, CT-155 for schizophrenia, NightWare for sleep disturbance, EndeavorRx for ADHD, and reSET/reSET-O for substance/opioid use disorders. Despite privacy concerns and limited physician awareness, digital therapeutics offer accessible, safe treatment options.

Inventiva secures €94.1 million of up to €348 million in equity financing to fund Phase 3 NATiV3 trial for lanifibranor in MASH, with over 1,100 patients enrolled; appoints Mark Pruzanski, MD as Chairman and Srinivas Akkaraju, MD, PhD as director.

Starting a biotech company involves navigating scientific validation, regulatory requirements, and fundraising challenges. Founders must choose the right focus, leverage university collaborations, attract investments, and build a strong team. Regulatory and IP strategies are crucial, and founders should be prepared for a long, challenging journey.

Thirty years after the discovery of microRNAs, which regulate gene activity, the Nobel Prize in Physiology or Medicine was awarded to their discoverers. Despite potential applications in treating cancer and heart disease, no microRNA-based drugs have been approved by the FDA. Early clinical trials faced challenges with delivery and immune response, but advancements in technology and increased interest from the Nobel Prize may drive future success in developing microRNA-based medicines.

Mpox vaccine protection wanes within 6-12 months, necessitating boosters, according to a study published in the Journal of the American Medical Association. The study, led by Dr. Ai-ris Yonekura Collier, found that vaccine-generated antibodies largely diminish over time, emphasizing the importance of completing the two-dose series and considering booster shots for continued protection.

Aptadir Therapeutics launches with RNA inhibitors for intractable cancers and genetic conditions, developed by top institutions. Giovanni Amabile appointed as Executive Chairman and acting CEO. Received $1.6m pre-seed funding from EXTEND, a biopharmaceutical technology transfer hub.

The TRIPOD+AI update provides harmonised guidance for reporting prediction model studies, superseding TRIPOD 2015, to accommodate AI and machine learning methods. The new 27-item checklist aims for complete, accurate, and transparent reporting, facilitating study appraisal and model implementation.